/PRNewswire/ Sumitomo Pharma Canada, Inc., announced today that ORGOVYX® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is.
/PRNewswire/ Sumitomo Pharma America, Inc. (SMPA), today announced the expansion of its partnership with actress and overactive bladder (OAB) patient Holly.
/PRNewswire/ Sumitomo Pharma America, Inc. (SMPA) today announced preliminary clinical data for investigational agents TP-3654, a selective oral PIM1 kinase.
Sumitomo Pharma Announces Authorization in Canada of ORGOVYX® (relugolix) for the Treatment of Men with Advanced Prostate Cancer lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE® streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.